A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals

European Journal of Immunology

Volumn 30, Issue 11, 2000, Pages 3338-3346

  Okugawa, Toshiharu ^a   Ikuta, Yasushi ^a   Takahashi, Yoshiyuki ^a   Obata, Hidenori ^a   Tanida, Koji ^a   Watanabe, Masato ^a   Imai, Shigemi ^b   Furugen, Reiko ^c   Nagata, Yasuhiro ^c   Toyoda, Nagayasu ^a   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY   (Japan)

^b Japanese Red Cross Society   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

Cytotoxic T lymphocyte; Dendritic cell; HER2 neu; Ovarian cancer; Tumor rejection antigen

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR REJECTION ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; KILLER CELL; MONONUCLEAR CELL; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; SENSITIZATION; SEQUENCE HOMOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; MICE; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033739243     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200011)30:11<3338::AID-IMMU3338>3.0.CO;2-3     Document Type: Article

References (35)

1. From defined human tumor antigens to effective immunization?
2. T cell defined tumor antigens
3. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
4. Peptide motifs of HLA-A3, -A24, and -B 7 molecules as determined by pool sequencing
5. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
6. Peptide derived from a wild-type murine proto-oncogene c-erbB-2/ HER2/neu can induce CTL and tumor suppression in syngeneic hosts
7. DNA typing of the HLA-A gene: Population study and identification of four new alleles in Japanese
8. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER2/neu proto-oncogene
9. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein
10. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer
11. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro
12. Identification of an immunodominant peptide of HER2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
13. Breast and ovarian cancerspecific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
14. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes
15. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A 2.1 and human CD.8
16. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes
17. The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors
18. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
19. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas
20. Poor binding of a HER-2/neu epitope (GP2) to HLA-A 2.1 is due to a lack of interactions with the center of the peptide
21. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization
22. Mutant MAP kinase. A tumor rejection antigen of mouse sarcoma
23. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells
24. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer
25. p185neu expression in human lung adenocarcinomas predicts shortened survival
26. Amplification and overexpression of the EGF receptor and c-erbB-2 protooncogenes in human stomach cancer
27. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues
28. Immunization with a peptide epitope (p369-377) from HER-2/neu leads peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors
29. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
30. HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies
31. NK susceptibility varies inversely with target cell class I HLA antigen expression
32. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
33. Proliferating dendritic cell progenitors in human blood
34. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
35. Definition of a unique cell surface antigen of mouse leukemia RL male 1 by cell-mediated cytotoxicity